Travere Therapeutics (TVTX) PT Raised to $19 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Travere Therapeutics (TVTX) PT Raised to $23 at Citi, 'Full Approval as Expected and We Expect Positive Inflection in Sales Trajectory'
September 6, 2024 9:49 AM EDTCiti analyst Carly Kenselaar raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $23.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "The FDA granted full approval of Filspari as expected, increasing the market size from the initial 30k-50k to... More
